pre-update Archives

Publication

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)

The article “Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL)…

Certara2024 年 8 月 26 日

Press Coverage

The Uncertain Path Forward for Psychedelic Medicine

Certara's Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this…

Certara2024 年 8 月 26 日

Blog

Streamline your clinical trials with automated metadata management

When it comes to efficient clinical study build, content is king. Most importantly: metadata content.…

Certara2024 年 8 月 26 日

Blog

Resmetirom: A pioneering NASH clinical program

Nonalcoholic fatty liver disease (NAFLD) is a condition wherein the liver stores excess fat. Nonalcoholic…

Certara2024 年 8 月 23 日

Press Coverage

克服细胞与基因治疗中的 CMC 挑战：第一部分

In this Manufacturing Chemist article, Certara's Drs. Hien Anh Bruno and Deven Shah discuss the…

Certara2024 年 8 月 23 日

Press Release

Certara 将参加即将举行的投资者会议

RADNOR, Pa. — 2024 年 8 月 21 日 -- Certara, Inc. （纳斯达克股票代码：CERT), a global leader in…

Certara2024 年 8 月 21 日

Blog

Quantitative Systems Pharmacology (QSP) Modeling for Immunotherapy-induced Cytokine Release Syndrome

Cytokine Release Syndrome Cytokine release syndrome (CRS) is an inflammatory immune reaction that clinically manifests…

Certara2024 年 8 月 20 日

On-Demand Webinar

驾驭新领域：FDA/EMA 合规联合建议 — 顺应欧盟法规动态

Presentation Materials

Certara2024 年 8 月 20 日

On-Demand Webinar

驾驭新领域：不断演变的欧盟法规对监管事务的影响

Presentation Materials Don't miss Part 2 in the series Joint Advice on FDA/EMA Compliance…

Certara2024 年 8 月 20 日

On-Demand Webinar

应用定量系统药理学（QSP）建模优化肿瘤学剂量

The FDA’s Project Optimus initiative aims to reform dose optimization and selection for oncology therapies…

Certara2024 年 8 月 19 日

pre-update

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)

The Uncertain Path Forward for Psychedelic Medicine

Streamline your clinical trials with automated metadata management

Resmetirom: A pioneering NASH clinical program

克服细胞与基因治疗中的 CMC 挑战：第一部分

Certara 将参加即将举行的投资者会议

Quantitative Systems Pharmacology (QSP) Modeling for Immunotherapy-induced Cytokine Release Syndrome

驾驭新领域：FDA/EMA 合规联合建议 — 顺应欧盟法规动态

驾驭新领域：不断演变的欧盟法规对监管事务的影响

应用定量系统药理学（QSP）建模优化肿瘤学剂量

订阅时事通讯

快捷链接

解决方案

联系我们